Inhibikase Therapeutics (IKT) Share-based Compensation Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | 172.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 172.24% |
| Dec 31, 2025 | -42.67% |
| Sep 30, 2025 | 2,957.08% |
| Jun 30, 2025 | 13,610.60% |
| Mar 31, 2025 | 3,721.90% |
| Dec 31, 2024 | 6,369.14% |
| Sep 30, 2024 | 14.06% |
| Jun 30, 2024 | -75.41% |
| Mar 31, 2024 | -56.65% |
| Dec 31, 2023 | 21.81% |
| Sep 30, 2023 | 27.50% |
| Jun 30, 2023 | -5.97% |
| Mar 31, 2023 | 0.04% |
| Dec 31, 2022 | -62.25% |
| Sep 30, 2022 | -71.12% |
| Jun 30, 2022 | -58.83% |
| Mar 31, 2022 | -79.15% |
| Dec 31, 2021 | 163.41% |
| Sep 30, 2021 | 152.16% |
| Jun 30, 2021 | 130.74% |